Secondary purposes were to observe the need for rescue antiemetics and assess patient satisfaction. Exclusion criteria, in part, were:
• recent antiemetic use
• recent emetogenic drug administration
• recent opioid use
• recent glucocorticoid use
• nausea or vomiting within 24 hours pre-op
• surgery-related postoperative complications
Women were randomly allocated into one of three groups:
• P6 acustimulation + dexamethasone • tropisetron + dexamethasone • dexamethasone only P6 acupoint electrical stimulation and the corresponding placebo were set up by the same investigator who was not involved in delivery of the anesthetic. In the P6 acustimulation group, the stimulating electrode was applied at the P6 acupoint location. The other electrode was placed on the dorsal forearm. The stimulating current was delivered at 2
Hz with square wave pulses of 0.2 ms in duration.
Current began at 1 mA and was increased until the patient felt discomfort. Ultimately, delivered current ranged from 6 mA to 20 mA. This stimulation began 30 minutes before induction of general anesthesia and continued until PACU discharge. In the tropisetron and dexamethasone only groups, P6 acustimulation was set up the same way but no current was delivered to the patient. Patients were told they might or might not feel the acustimulation. with atropine up to 2.5 mg. In the PACU, morphine was given if additional pain medicine was requested.
All patients were interviewed at 2 h, 6 h, 24 h, and 48h post-op and questioned about nausea, vomiting, retching, and pain (VAS 0 to 10). At 48 hours, satisfaction was assessed on a 0-100 mm visual analog scale from 0= very dissatisfied to 100= most satisfied imaginable.
Result

PONV risk factors, intraoperative
fentanyl administration, neostigmine dose, IV fluid administered, and morphine administered postoperatively were all similar between groups. The global rate of nausea including all patients in all three groups was 35% and vomiting 19%.
Both P6 acustimulation + dexamethasone and tropisetron + dexamethasone prevented PONV better than dexamethasone alone. The group rates of PONV during the first 24 hours post-op were:
• P6 acustimulation group 28% • tropisetron group 26% • dexamethasone alone group 50%
The need for rescue antiemetic administration was similar between groups. Patient satisfaction was also similar between groups. The length of PACU stay was statistically significantly different between groups, but the difference was only 5 minutes.
Conclusion
Transcutaneous electrical stimulation at the P6 point combined with dexamethasone resulted in antiemetic prophylaxis similar to that of tropisetron with dexamethasone and better than dexamethasone alone.
Comment
Stimulating a point on the surface of the skin, a la acupuncture, may seem strange to us in the west. To my knowledge we don't have a scientific foundation to explain it. I'll admit, these types of things seem very strange to me, and I'm slow to accept them without very good reason. But, at the same time I have to remind myself of the number of perfectly good drugs for which the mechanism of action is "unknown;" yet, we know from long experience that they work. rate of planned cesarean deliveries increased 21%, and the rate of unplanned cesarean deliveries increased 17% (P < 0.0001 for both). The age and rate of comorbidity increased significantly over the study period. There was a 13% increase in the proportion of women over 40 years old (P < 0.0001), and the proportion of women with at least one comorbid condition increased 9% (P < 0.0001).
Of these 785,854 discharges, there were 5,715 discharges with at least one anesthesia-related adverse event (rate = 730 per 100,000). There were a total of 11,093 adverse events recorded in these 5,715
discharges; a median of 2 adverse events per discharge. There were 7,040 non-anesthetic complications (890 per 100,000) and 266 cardiac arrests or deaths (cardiac arrest rate = 22 per 100,000; death rate = 23 per 100,000). The overall rate of anesthesia-related adverse events decreased 25% (P < 0.0001). This rate of decrease was seen for planned (34% decrease; P < 0.0001) and unplanned cesarean deliveries (16%; P < 0.0001). The decrease was observed in rural and urban hospitals, as well as those with residency programs. The rate of anesthesiarelated adverse events decreased to a greater extent for major events compared to minor events (43% vs.
23%; Figure 1 ). 
. Adverse Events after Cesarean Delivery
In contrast, non-anesthesia complication rates increased 47% from 2003 to 2012 (P < 0.0001; Figure   1 ). This increase was seen regardless of the cesarean delivery being planned (36% increase) or unplanned (57% increase; both P < 0.0001). The rate of disseminated intravascular coagulation increased 78%, and the rate of kidney failure increased 127%
(P < 0.0001).
Conclusion
Major anesthesia-related adverse events accounted for 5.7% of all adverse events.
Overall, anesthesia-related adverse events in cesarean delivery decreased 25% in New York state; however, anesthesia-related adverse events during cesarean delivery under general anesthesia did not change. The decrease in anesthesia-related adverse events paralleled the increased use of regional anesthesia for cesarean section.
Comment
These study results demonstrate that our obstetric patients are getting older and sicker. The results demonstrated this dosing regimen was safe and effective at reducing Emergence Agitation when compared to saline. One would expect, as the investigators found, that the heart rate will be lower after administration of dexmedetomidine, and that there will be a slight increase in blood pressure transiently after its administration. Otherwise, the hemodynamic responses were very similar to saline.
While dexmedetomidine was effective in decreasing Emergence Agitation, it did prolong the PACU length of stay in the investigators' outpatient surgery center.
No difference was found in their hospital setting.
There 
Result
The ondansetron and placebo groups had no significant demographic differences. When pruritus occurred, it began in slightly less than three hours in both groups.
The duration of pruritus was also similar in both groups at 13 h to 14 h. However, the incidence of pruritus was 16% (4 women) in the ondansetron group vs. 88% ( Comparison of Nausea such good pain relief. While some studies were better than whatever they were comparing against, none ever made me think, "There, the problem is solvedall we have to do is ..." This study had a simple, appropriate methodology, and a proper analysis; the results show the greatest reduction in both pruritus and nausea I ever remember seeing. What is different about this study than all the others? The only thing I see is that they gave the ondansetron 30 minutes before they did the spinal with morphine. Maybe that is the "aha" we've been looking for. In any case, given the extremely low risk, it is well worth trying. ratio ≤0.7. On average, the sugammadex group was ready to leave the OR four minutes faster than the neostigmine group.
"Adverse Events" occurred at a similar rate in both groups. They were mostly judged to be "mild" or "moderate" in severity. However, 10% of patients in both groups had a "serious" adverse event, none of which involved respiration and each of which were unlikely to have been related to the study drug (e.g., gastrointestinal bleeding). There was an exception to this, however; two neostigmine patients had clinically significant skeletal muscle weakness judged to be related to the study drug. One of these cases involved re-paralysis 60 minutes after neostigmine administration in a patient who had received a total of Also, there was no evidence of allergic reaction in sugammadex patients.
Conclusion
No patients who received sugammadex had residual neuromuscular block upon arrival in the PACU. Forty-three percent of patients who received neostigmine had residual neuromuscular block upon arrival in the PACU. In some cases this residual block was quite profound.
Comment
This study makes me want to write a comment that is way too long so I'm going to hit just a couple points. I accept the fact that those of you who know me are laughing.
This study was conducted at a major, big name, east coast USA hospital. So imagine my surprise that 33% of the time, expert anesthesia providers were using neostigmine incorrectly. Either they were trying to reverse a block with no idea how deep the block was (no neuromuscular block monitoring) or they were trying to reverse a block that they knew was too deep to reverse, like 0 twitches on a Train-of-4. Another surprise to me was the average dose of neostigmine used, only 0.052 mg/kg or about 3.6 mg in a On arrival to the PACU, a TOF-watch was used to quantify the Train-of-4 ratio. Between groups, no differences were seen in the:
• total rocuronium administered • frequency of rocuronium administration within last 45 minutes of procedure • Train-of-4 count at time of reversal • time from administration of neostigmine to extubation • total neostigmine dose The investigators did not present differences in opioid use between the two groups.
The rate of Residual Neuromuscular Block (Trainof-4 < 0.9) was significantly greater in the old group; 57.7% vs. 30% (P < 0.001). The rate of moderate and severe Residual Neuromuscular Block was also significantly greater in the old group (P < 0.01; Figure   1 ). Significantly more oxygen desaturations to 90%-94% occurred in the old group (38% vs. 17%, P <0.001). Old group patients also had higher rates of pulmonary complications during their hospital stay (15% vs. 2%, P < 0.001). Patient reports of general weakness were similar in the old group (72%) and young group (58%) on PACU admission (P = NS) However, 20 minutes after admission the old group reported significantly greater weakness; 60% vs. 36%.
(P < 0.001). Time until PACU discharge readiness was 5 minutes longer in the old group (P = NS). But time until actual discharge was 14 minutes longer in the old group (P < 0.001). despite all patients receiving reversal at the end of the surgery. To me these results speak to the need for increased availability of quantitative monitors to monitor the TOF ratio. Current recommendations are only to extubate with a TOF >0.9.
Unfortunately, these devices are expensive; therefore,
we still have to rely on our qualitative monitors. Steps you can take are to: (1) be judicious in your use of muscle relaxants; (2) There are some limitations to these results. The investigators should have used multivariate regression analysis to control for group differences that could have affected the outcomes. Specifically, patients in the older cohort had higher rates of obstructive sleep apnea (10.7% vs. 6.7%) and diabetes (14.1% vs.
3.3%). Additionally, patients in the younger group with residual neuromuscular blockade had significantly higher rates of obstructive sleep apnea (13.3% vs. 3.8%). Nonetheless, I still believe these results are important and speak to the need to rely on the tips I suggested above.
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